Skip to main content

Advertisement

SpringerLink
Log in

Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT

  • Original Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

Background

In the recent years, surgical resection with pre- and/or postoperative chemotherapy has markedly improved the survival rate of hepatoblastoma patients. We herein report the results of patients treated with the current protocol of the Japanese Study Group for Pediatric Liver Tumor, JPLT-2.

Methods

A total of 279 patients with malignant liver tumor were enrolled in JPLT-2. Data from 212 hepatoblastoma cases were analyzed. PRETEXT I patients were treated with primary resection followed by low doses of cisplatin–pirarubicin (tetrahydropyranyl-adriamycin). Otherwise, patients received preoperative cisplatin–pirarubicin (CITA), followed by surgery and postoperative chemotherapy. Ifosfamide, pirarubicin, etoposide, and carboplatin (ITEC) were given as a salvage treatment. High-dose chemotherapy with hematopoietic stem cell transplantation (SCT) was reserved for patients with metastatic diseases.

Results

The 5-year overall survival rate (OS) in non-metastatic cases was 100% for PRETEXT I, 87.1% for PRETEXT II, 89.7% for PRETEXT III, and 78.3% for PRETEXT IV. The 5-year OS in metastatic cases was 43.9%. The outcome in non-metastatic PRETEXT IV cases was markedly improved, while the results of metastatic tumors remained poor.

Conclusions

JPLT-2 protocol achieved satisfactory survival among children with non-metastatic hepatoblastoma. New approaches are needed for patients with metastatic diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 18:2665–2675

    CAS  PubMed  Google Scholar 

  2. Fuchs J, Rydzynski J, von Shweinitz D et al (2002) Pretreatment prognostic factors and treatment results in children with hepatoblastoma. A report from the German Cooperative Pediatric Liver Tumour Study HB94. Cancer 95:172–182

    Article  PubMed  Google Scholar 

  3. Perilongo G, Shafford E, Maibach R et al (2004) Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology––SIOPEL 2. Eur J Cancer 40:411–421

    Article  CAS  PubMed  Google Scholar 

  4. Sasaki F, Matsunaga T, Iwafuchi M et al (2002) Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: a report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg 37:851–856

    Article  CAS  PubMed  Google Scholar 

  5. Katzenstein HM, London WB, Douglass EC et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group Phase II Study. J Clin Oncol 20:3438–3444

    Article  PubMed  Google Scholar 

  6. Matsunaga T, Sasaki F, Ohira M et al (2003) Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 19:142–146

    PubMed  Google Scholar 

  7. Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 24:2879–2884

    Article  CAS  PubMed  Google Scholar 

  8. Czauderna P, Otte JB, Aronson DC et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era––recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031–1036

    Article  PubMed  Google Scholar 

  9. Tagge EP, Tagge DU, Reyes J et al (1992) Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival. J Pediatr Surg 27:292–297

    Article  CAS  PubMed  Google Scholar 

  10. King DR, Ortega J, Campbell J et al (1991) The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy. J Pediatr Surg 26:1074–1081

    Article  CAS  PubMed  Google Scholar 

  11. Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361:1662–1670

    Article  CAS  PubMed  Google Scholar 

  12. Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblatoma––results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1. Eur J Cancer 36:1418–1425

    Article  CAS  PubMed  Google Scholar 

  13. Aronson DC, Schnater JM, Staalman CR et al (2005) Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Grou p SIOPEL-1 study. J Clin Oncol 23:1245–1252

    Article  PubMed  Google Scholar 

  14. Meyers RL, Rowland JR, Krailo M et al (2009) Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 53:1016–1022

    Article  PubMed  Google Scholar 

  15. Koh E, Ueda Y, Nakamura T, Kobayashi A, Katsuta S, Takahashi H (2002) Apoptosis in young rats with adriamycin-induced cardiomyopathy––comparison with pirarubicin, a new anthracycline derivative. Pediatr Res 51:256–259

    Article  CAS  PubMed  Google Scholar 

  16. Zsíros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590

    Article  PubMed  Google Scholar 

  17. Otte JB, Oritchars J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the international society of pediatric oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83

    Article  CAS  PubMed  Google Scholar 

  18. Otte JB, de Goyet JV, Reding R (2005) Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 9:557–565

    Article  PubMed  Google Scholar 

  19. Reyes JD, Carr B, Dvorchik I et al (2000) Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. J Pediatr 136:795–804

    Article  CAS  PubMed  Google Scholar 

  20. Tanaka K, Uemoto S, Tokunaga Y et al (1993) Surgical techniques and innovations in living related liver transplantation. Ann Surg 217:82–91

    Article  CAS  PubMed  Google Scholar 

  21. Kasahara M, Ueda M, Haga H et al (2005) Living-donor liver transplantation for hepatoblastoma. Am J Transplant 5:2229–2235

    Article  PubMed  Google Scholar 

  22. Nishimura S, Sato T, Fujita N et al (2002) High-dose chemotherapy in children with metastatic hepatoblastoma. Pediatr Int 44:300–305

    Article  CAS  PubMed  Google Scholar 

  23. Yoshinari M, Imaizumi M, Hayashi Y et al (1998) Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: a therapeutic approach for incompletely resected tumor. Tohoku J Exp Med 184:247–254

    Article  CAS  PubMed  Google Scholar 

  24. Kitahara S, Makuuchi M, Ishizone S et al (1995) Successful left trisegmentectomy for ruptured hepatoblastoma using intraoperative transarterial embolization. J Pediatr Surg 30:1709–1712

    Article  CAS  PubMed  Google Scholar 

  25. Iida T, Senaga M, Takeuchi Y et al (2004) Successful resection of a ruptured hepatoblastoma prior to chemotherapy: report of a case. Surg Today 34:710–714

    Article  PubMed  Google Scholar 

  26. Hara J, Osugi Y, Ohta H et al (1998) Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric tumors. Bone Marrow Transplant 22:7–12

    Article  CAS  PubMed  Google Scholar 

  27. Suita S, Tajiri T, Takamatsu H et al (2004) Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen––a report from the study group for pediatric solid malignant tumors in the Kyushu area. J Pediatr Surg 39:195–198

    Article  CAS  PubMed  Google Scholar 

  28. von Schweinitz D, Hecker H, Harmas D et al (1995) Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma––a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 30:845–852

    Article  Google Scholar 

  29. Katzenstein HM, Rigsby C, Shaw PH et al (2002) Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 24:751–755

    Article  PubMed  Google Scholar 

  30. Palmer RD, Williams DM (2003) Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 41:78–80

    Article  PubMed  Google Scholar 

  31. Ijichi O, Ishikawa S, Shinkoda Y et al (2006) Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. Pediatr Transplant 10(5):635–638

    Article  PubMed  Google Scholar 

  32. Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 25:4622–4627

    Article  CAS  PubMed  Google Scholar 

  33. Qayed M, Powell C, Morgan ER et al (2010) Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 54:761–763

    PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank all the staff at institutes that participated in JPLT for enrolling their patients into the study. We also thank the following previous core members of JPLT, who participated in designing the initial JPLT-2 protocol in 1998; Drs. Yutaka Hayashi, Akira Hayashi, Kohei Hashizume, Hideo Mugishima.

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Pediatric Surgery, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

    Tomoro Hishiki, Tadashi Matsunaga & Naomi Ohnuma

  2. Department of Pediatric Surgery, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638, Japan

    Fumiaki Sasaki

  3. Department of Pediatrics, Akita University School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan

    Michihiro Yano

  4. Department of Pediatrics, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Kohmei Ida

  5. Division of Pathology, Chiba Children’s Hospital, 579-1 Heta-cho, Midori-ku, Chiba, 266-0007, Japan

    Hiroshi Horie

  6. Division of Pediatric Surgery and Transplant Surgery, Nagoya City University Medical School, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan

    Satoshi Kondo

  7. Department of Pediatrics, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

    Ken-Ichiro Watanabe

  8. Division of Pediatric Surgery, Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Takaharu Oue

  9. Department of Pediatric Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan

    Tatsuro Tajiri

  10. Department of Pediatric Surgery, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan

    Arata Kamimatsuse & Eiso Hiyama

Authors
  1. Tomoro Hishiki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadashi Matsunaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumiaki Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michihiro Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kohmei Ida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroshi Horie
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Satoshi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ken-Ichiro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takaharu Oue
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tatsuro Tajiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Arata Kamimatsuse
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Naomi Ohnuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Eiso Hiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoro Hishiki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hishiki, T., Matsunaga, T., Sasaki, F. et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 27, 1–8 (2011). https://doi.org/10.1007/s00383-010-2708-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-010-2708-0

Keywords

Search

Navigation